1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GLOBAL PRENATAL TESTING MARKET, BY TECHNIQUE
5.1. Introduction
5.2. Non-invasive
5.2.1. Sonography
5.2.2. Biochemical Screening Tests
5.2.3. Cell-Free DNA Screening Tests
5.3. Invasive
5.3.1. Amniocentesis
5.3.2. Chorionic Villus Sampling (CVS)
6. GLOBAL PRENATAL TESTING MARKET, BY INDICATION
6.1. Introduction
6.2. Genetic Diseases
6.3. Infectious Diseases
7. GLOBAL PRENATAL TESTING MARKET, BY END-USER
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Diagnostic Labs
8. GLOBAL PRENATAL TESTING MARKET, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Agilent Technologies, Inc.
10.2. Invitae Corporation
10.3. Illumina, Inc.
10.4. Laboratory Corporation of America® Holdings
10.5. Natera, Inc.
10.6. Quest Diagnostics Incorporated
10.7. F. Hoffmann-La Roche Ltd
10.8. BGI Diagnosis Co., Ltd
10.9. IGENOMIX S.L.